Roche, the pharmaceutical giant, acquired health tech startup Flatiron Health in 2018 for $1.9 billion to enhance its access to real-world evidence and boost its cancer drug development efforts. Flatiron, known for its oncology-focused electronic health record software and real-world cancer data repository, has partnered with numerous cancer centers and global oncology therapeutics developers. The acquisition was a strategic move to support Roche's personalized healthcare initiatives, with the aim of accelerating new cancer treatments by leveraging high-quality, curated data.
However, Roche is now reportedly considering divesting Flatiron Health, according to sources cited by the Financial Times. The Swiss pharma company has engaged Citigroup to explore options, which could include selling the business or bringing in a partner to help manage it. Roche's ownership of Flatiron has deterred other drugmakers from collaborating with the startup, leading to challenges in driving sales. Despite this, Flatiron has continued to secure partnerships, particularly with healthcare and academic organizations, and has expanded its operations in Japan, Germany, and the U.K.
Flatiron has maintained a separate business entity under Roche, but its potential divestment reflects ongoing strategic shifts within Roche, marked by significant leadership changes since the acquisition. Flatiron recently renewed its partnership with the FDA and has collaborated with organizations like Leeds Teaching Hospitals NHS Trust and AI-focused Lifebit to advance cancer research. The company's ongoing efforts to integrate technology into clinical trials and expand its global presence underscore its commitment to revolutionizing oncology care, even as Roche evaluates its future role within the organization.
Click here to read the original news story.